Cutler Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cutler Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,100	Closed	-$78K	–	5723
2021 Q3	$78K	Sell	1,100 -200	-15%	-$30.2K	﹤0.01%	2125
2021 Q2	$89K	Buy	+1,300	New	+$225K	﹤0.01%	1983
2018 Q4	–	Sell	-1,500	Closed	-$1K	–	4263
2018 Q3	$1K	Buy	+1,500	New	+$258K	﹤0.01%	3781
2018 Q1	–	Sell	-1,500	Closed	-$1K	–	4829
2017 Q4	$1K	Sell	1,500 -200	-12%	-$27.7K	﹤0.01%	4483
2017 Q3	$20K	Sell	1,700 -17,700	-91%	-$2.68M	﹤0.01%	3140
2017 Q2	$107K	Buy	19,400 +11,900	+159%	+$1.82M	﹤0.01%	1804
2017 Q1	$55K	Sell	7,500 -9,100	-55%	-$1.19M	﹤0.01%	2323
2016 Q4	$30K	Buy	16,600 +700	+4%	+$78K	﹤0.01%	3053
2016 Q3	$22K	Buy	15,900 +2,000	+14%	+$270K	﹤0.01%	3328
2016 Q2	$120K	Buy	13,900 +1,000	+8%	+$147K	0.01%	1536
2016 Q1	$77K	Buy	+12,900	New	+$1.61M	0.01%	1875

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cutler Group's JAZZ Position: Q1 2023 in Review

Cutler Group sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 100 shares — an estimated $15K sold.

Cutler Group first reported a position in JAZZ in Q4 2015 and held it in 18 quarters. The position peaked at $1.62M in Q4 2015. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Cutler Group reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Cutler Group sold 100 Jazz Pharmaceuticals shares in Q1 2023, an estimated $15K.
Cutler Group first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 18 quarters.
Cutler Group's Jazz Pharmaceuticals position peaked at $1.62M in Q4 2015.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.